drugset

drugset / Trial / NCT05119686

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

NCT05119686 ↗

Phase 2 Completed 140 enrolled Arthrosi Therapeutics

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.

Timeline

Start: 2021-11-16
Primary completion: 2022-11-17
Completion: 2022-11-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AR882	Unknown	—	Oral

Indications